Prevalence of immune-related adverse events and anti-tumor efcacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors

While immune checkpoint inhibitors (ICIs) occasionally cause immune-related adverse events (irAEs) in various organs, the prevalence of irAEs and potential risk factors have not been clarified. We identified irAE predictive factors and examined the relationship between the effect of ICIs and irAEs for patients with malignancies.